(2E,4E,8Z,11E)-N-(2-hydroxy-2-methylpropyl)tetradeca-2,4,8,11-tetraenamide

Details

Top
Internal ID 1a557cb1-d20f-41e4-83c5-d782cb7b58fb
Taxonomy Lipids and lipid-like molecules > Fatty Acyls > Fatty amides > N-acyl amines
IUPAC Name (2E,4E,8Z,11E)-N-(2-hydroxy-2-methylpropyl)tetradeca-2,4,8,11-tetraenamide
SMILES (Canonical) CCC=CCC=CCCC=CC=CC(=O)NCC(C)(C)O
SMILES (Isomeric) CC/C=C/C/C=C\CC/C=C/C=C/C(=O)NCC(C)(C)O
InChI InChI=1S/C18H29NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-17(20)19-16-18(2,3)21/h5-6,8-9,12-15,21H,4,7,10-11,16H2,1-3H3,(H,19,20)/b6-5+,9-8-,13-12+,15-14+
InChI Key HSFPMLIZJAVYHM-NPNWTSAVSA-N
Popularity 3 references in papers

Physical and Chemical Properties

Top
Molecular Formula C18H29NO2
Molecular Weight 291.40 g/mol
Exact Mass 291.219829168 g/mol
Topological Polar Surface Area (TPSA) 49.30 Ų
XlogP 3.50
Atomic LogP (AlogP) 3.68
H-Bond Acceptor 2
H-Bond Donor 2
Rotatable Bonds 10

Synonyms

Top
SCHEMBL1030111
BDBM50494418

2D Structure

Top
2D Structure of (2E,4E,8Z,11E)-N-(2-hydroxy-2-methylpropyl)tetradeca-2,4,8,11-tetraenamide

3D Structure

Top

ADMET Properties (via admetSAR 2)

Top
Target Value Probability (raw) Probability (%)
Human Intestinal Absorption + 0.9810 98.10%
Caco-2 + 0.7881 78.81%
Blood Brain Barrier + 0.8500 85.00%
Human oral bioavailability - 0.5429 54.29%
Subcellular localzation Mitochondria 0.6454 64.54%
OATP2B1 inhibitior - 0.8573 85.73%
OATP1B1 inhibitior + 0.8066 80.66%
OATP1B3 inhibitior + 0.9426 94.26%
MATE1 inhibitior - 0.9600 96.00%
OCT2 inhibitior - 0.8000 80.00%
BSEP inhibitior + 0.7976 79.76%
P-glycoprotein inhibitior - 0.7038 70.38%
P-glycoprotein substrate - 0.7506 75.06%
CYP3A4 substrate - 0.5152 51.52%
CYP2C9 substrate - 1.0000 100.00%
CYP2D6 substrate - 0.8887 88.87%
CYP3A4 inhibition - 0.6480 64.80%
CYP2C9 inhibition - 0.7852 78.52%
CYP2C19 inhibition - 0.8127 81.27%
CYP2D6 inhibition - 0.8360 83.60%
CYP1A2 inhibition - 0.7280 72.80%
CYP2C8 inhibition - 0.7766 77.66%
CYP inhibitory promiscuity - 0.7899 78.99%
UGT catelyzed + 1.0000 100.00%
Carcinogenicity (binary) - 0.6700 67.00%
Carcinogenicity (trinary) Non-required 0.6025 60.25%
Eye corrosion - 0.9138 91.38%
Eye irritation - 0.8466 84.66%
Skin irritation - 0.7903 79.03%
Skin corrosion - 0.9434 94.34%
Ames mutagenesis - 0.6400 64.00%
Human Ether-a-go-go-Related Gene inhibition - 0.3805 38.05%
Micronuclear - 0.7300 73.00%
Hepatotoxicity - 0.6875 68.75%
skin sensitisation - 0.8838 88.38%
Respiratory toxicity - 0.5778 57.78%
Reproductive toxicity - 0.8111 81.11%
Mitochondrial toxicity - 0.6000 60.00%
Nephrotoxicity - 0.6968 69.68%
Acute Oral Toxicity (c) III 0.6697 66.97%
Estrogen receptor binding + 0.6394 63.94%
Androgen receptor binding - 0.7564 75.64%
Thyroid receptor binding + 0.6512 65.12%
Glucocorticoid receptor binding + 0.5918 59.18%
Aromatase binding + 0.5544 55.44%
PPAR gamma + 0.7823 78.23%
Honey bee toxicity - 0.9450 94.50%
Biodegradation - 0.8000 80.00%
Crustacea aquatic toxicity - 0.5500 55.00%
Fish aquatic toxicity - 0.6697 66.97%

Targets

Top

Proven Targets:

CHEMBL ID UniProt ID Name Min activity Assay type Source
CHEMBL218 P21554 Cannabinoid CB1 receptor 2400 nM
IC50
PMID: 24175626
CHEMBL253 P34972 Cannabinoid CB2 receptor 9100 nM
IC50
PMID: 24175626

Predicted Targets (via Super-PRED):

CHEMBL ID UniProt ID Name Probability Model accuracy
CHEMBL1293267 Q9HC97 G-protein coupled receptor 35 93.91% 89.34%
CHEMBL2581 P07339 Cathepsin D 93.57% 98.95%
CHEMBL3251 P19838 Nuclear factor NF-kappa-B p105 subunit 91.12% 96.09%
CHEMBL3060 Q9Y345 Glycine transporter 2 88.16% 99.17%
CHEMBL1907591 P30926 Neuronal acetylcholine receptor; alpha4/beta4 85.24% 100.00%
CHEMBL253 P34972 Cannabinoid CB2 receptor 84.59% 97.25%
CHEMBL1293249 Q13887 Kruppel-like factor 5 83.29% 86.33%
CHEMBL4793 Q86TI2 Dipeptidyl peptidase IX 82.23% 96.95%
CHEMBL2111367 P27986 PI3-kinase p110-alpha/p85-alpha 82.16% 94.33%
CHEMBL3401 O75469 Pregnane X receptor 80.85% 94.73%

Cross-Links

Top
PubChem 14135320
NPASS NPC44193
ChEMBL CHEMBL505802
LOTUS LTS0249106
wikiData Q105033014